Abstract Library

#3646 Thymic neuroendocrine neoplasms – Data from the Czech Neuroendocrine Tumor Registry 2008 – 2022

Introduction: Thymic neuroendocrine neoplasms are very rare, their incidence is only 3% of all NENs a 5% of thymic tumors. On ENETS 2022 Sarah Fodil—Cherif et alt. presented data of 74 patients with thymic NETs from retrospective French study (1988-2020) and their analysis.

Conference:

Presenting Author:

Authors: Sedlackova E, Barkmanova J, Linke Z, Karpianusova T,

Keywords: thymic neoplasms, neuroendocrine tumor,

#3051 Epidemiology, Pathological and Clinical Features of 4307 Patients with Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NEN) of the Spanish Neuroendocrine Cancer Registry (R-GETNE)

Introduction: RGETNE national NEN Registry comprises 74 hospitals from all regions of Spain.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Garcia Carbonero R, Jimenez-Fonseca P, Benavent M, Alonso V, Alonso T,

Keywords: GEP-NEN, tumor registry, survival, prognosis, epidemiology,

#817 Surgery after Peptide Receptor Radionuclide Therapy (PRRT) in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Introduction: There are a few case reports on surgery after peptide receptor radionuclide therapy (PRRT).

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Bertani E, Chiappa A, Fazio N, Grana C, Bodei L,

Keywords: neuroendocrine tumors, peptide receptor radionuclide therapy, surgery, survival, progression-free survival,

#557 The Role of Chemotherapy in the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): The Large Experience of the Spanish National Tumor Registry (RGETNE)

Introduction: GEPNETs represent a heterogenous family of tumors of challenging clinical management. Treatment of advanced disease is evolving, including some recent relevant achievements with novel targeted agents. How to best integrate these new agents with conventional chemotherapy(CT) is still a matter of debate.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Garcia-Carbonero R, Capdevila J, Jimenez-Fonseca P, Alonso V, Pachon V,

Keywords: chemotherapy,

#389 Czech Neuroendocrine Tumor Registry - 28 Months Results

Introduction: Cooperative Group for NET was established on 22 April 2008. It continues with the practices of the Czech Carcinoid Group since 1998. The real incidence of neuroendocrine tumors is unknown. The majority remain undiagnosed. Therefore, the Czech Registry started in October 2009 to identify NET patients and to facilitate the diagnosis and therapy in centers with NET experts.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Barkmanova J, Honova H, Louthan O, Sedlackova E, Novak J,

Keywords: NET, registry, database, Czech Republic,